• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

初级保健中阿片类药物及其他物质使用障碍数字疗法实施情况的形成性评估(DIGITS试验)。

Formative evaluation of the implementation of digital therapeutics for opioids and other substance use disorders in primary care (DIGITS trial).

作者信息

Palazzo Lorella, Dorsey Caitlin N, Mogk Jess, Beatty Tara, King Deborah, Stefanik-Guizlo Kelsey, Key Dustin, Matson Tessa E, Shea Mary, Caldeiro Ryan M, McWethy Angela Garza, Wong Edwin S, Idu Abisola E, Glass Joseph E

机构信息

Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.

Kaiser Permanente Washington Mental Health & Wellness Services, Seattle, WA, USA.

出版信息

Implement Res Pract. 2024 Dec 12;5:26334895241301670. doi: 10.1177/26334895241301670. eCollection 2024 Jan-Dec.

DOI:10.1177/26334895241301670
PMID:39676816
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11639013/
Abstract

BACKGROUND

Substance use disorders (SUDs) result in individual and societal burden. However, most individuals with SUD receive no treatment. Implementing SUD interventions in primary care could address this population's treatment needs. In the USA, reSET and reSET-O were the first prescription digital therapeutics (PDTs) for SUDs and opioid use disorder (OUD), respectively. The Digital Treatments for Substance Use Disorder (DIGITS) study tested the effectiveness of practice facilitation and health coaching strategies to support reSET and reSET-O implementation into primary care. A formative evaluation was conducted to monitor implementation, inform adaptations, and learn what promotes PDT sustainment.

METHOD

The Dynamic Sustainability Framework and the Framework for Reporting Adaptations and Modifications to Evidence-based Implementation Strategies guided the evaluation. Using rapid qualitative methods, we collected and analyzed observational fieldnotes, key informant interviews, and document sources (e.g., meeting minutes) for synthesis and dissemination to clinical partners and the study team via formative reports. We analyzed the reports to generate evaluation results.

RESULTS

Twenty-four primary care clinics participated. Evaluation data included 98 observational fieldnotes, 16 interviews, and 253 document sources. We produced nine formative reports. The study encountered barriers and facilitators in each DSF domain (ecological system, practice setting, and intervention). In the ecological system, the PDT vendor enabled the study, but the COVID-19 pandemic, laws, regulations, and contracting delayed implementation. In the practice setting, staff shortages and low clinic capacity were implementation challenges, while electronic health record capabilities were both barriers and facilitators. At the intervention level, non-routine workflows, clinician burden, and low patient engagement were barriers despite clinicians' efforts.

CONCLUSIONS

Digital therapeutics are promising SUD and OUD treatments, but integration into primary care requires conducive laws and regulations, organizational capacity, and patient and clinician engagement. Formative evaluation identified important lessons for future PDT implementation.

摘要

背景

物质使用障碍(SUDs)给个人和社会带来负担。然而,大多数患有物质使用障碍的人未接受治疗。在初级保健中实施物质使用障碍干预措施可以满足这一人群的治疗需求。在美国,reSET和reSET - O分别是首批用于物质使用障碍和阿片类物质使用障碍(OUD)的处方数字疗法(PDTs)。物质使用障碍数字疗法(DIGITS)研究测试了实践促进和健康指导策略对支持将reSET和reSET - O纳入初级保健的有效性。进行了一项形成性评估,以监测实施情况、为调整提供信息,并了解促进数字疗法持续应用的因素。

方法

动态可持续性框架以及基于证据的实施策略的调整和修改报告框架指导了此次评估。我们采用快速定性方法,收集并分析了观察性现场记录、关键信息提供者访谈以及文档资料(如会议记录),以便通过形成性报告进行综合分析并传达给临床合作伙伴和研究团队。我们分析这些报告以得出评估结果。

结果

24家初级保健诊所参与了研究。评估数据包括98份观察性现场记录、16次访谈和253份文档资料。我们撰写了9份形成性报告。该研究在动态可持续性框架的每个领域(生态系统、实践环境和干预措施)都遇到了障碍和促进因素。在生态系统方面,数字疗法供应商推动了研究,但新冠疫情、法律法规和合同签订延误了实施进程。在实践环境中,人员短缺和诊所能力低下是实施过程中的挑战,而电子健康记录功能既是障碍也是促进因素。在干预层面,尽管临床医生付出了努力,但非常规工作流程、临床医生负担以及患者参与度低仍是障碍。

结论

数字疗法对于物质使用障碍和阿片类物质使用障碍是很有前景的治疗方法,但要纳入初级保健需要有利的法律法规、组织能力以及患者和临床医生的参与。形成性评估为未来数字疗法的实施提供了重要经验教训。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d526/11639013/44a881ec8be6/10.1177_26334895241301670-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d526/11639013/7507f42c354c/10.1177_26334895241301670-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d526/11639013/44a881ec8be6/10.1177_26334895241301670-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d526/11639013/7507f42c354c/10.1177_26334895241301670-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d526/11639013/44a881ec8be6/10.1177_26334895241301670-fig2.jpg

相似文献

1
Formative evaluation of the implementation of digital therapeutics for opioids and other substance use disorders in primary care (DIGITS trial).初级保健中阿片类药物及其他物质使用障碍数字疗法实施情况的形成性评估(DIGITS试验)。
Implement Res Pract. 2024 Dec 12;5:26334895241301670. doi: 10.1177/26334895241301670. eCollection 2024 Jan-Dec.
2
Study protocol for a factorial-randomized controlled trial evaluating the implementation, costs, effectiveness, and sustainment of digital therapeutics for substance use disorder in primary care (DIGITS Trial).一项评估初级保健中物质使用障碍数字治疗实施、成本、效果和可持续性的析因随机对照试验研究方案(DIGITS 试验)。
Implement Sci. 2023 Feb 1;18(1):3. doi: 10.1186/s13012-022-01258-9.
3
Prescription Digital Therapeutics for Substance Use Disorder in Primary Care: Mixed Methods Evaluation of a Pilot Implementation Study.初级保健中物质使用障碍的处方数字疗法:一项试点实施研究的混合方法评估。
JMIR Form Res. 2024 Sep 2;8:e59088. doi: 10.2196/59088.
4
Integrating Routine Screening for Opioid Use Disorder into Primary Care Settings: Experiences from a National Cohort of Clinics.将阿片类药物使用障碍的常规筛查纳入初级保健环境:来自全国诊所队列的经验。
J Gen Intern Med. 2023 Feb;38(2):332-340. doi: 10.1007/s11606-022-07675-2. Epub 2022 May 25.
5
Real-world use and clinical outcomes after 24 weeks of treatment with a prescription digital therapeutic for opioid use disorder.使用处方数字治疗药物治疗阿片类药物使用障碍 24 周后的真实世界应用和临床结局。
Hosp Pract (1995). 2021 Dec;49(5):348-355. doi: 10.1080/21548331.2021.1974243. Epub 2021 Sep 3.
6
Implementation and workflow strategies for integrating digital therapeutics for alcohol use disorders into primary care: a qualitative study.将数字治疗方法用于酒精使用障碍的实施和工作流程策略,纳入初级保健:一项定性研究。
Addict Sci Clin Pract. 2023 May 8;18(1):27. doi: 10.1186/s13722-023-00387-w.
7
Al-Anon Intensive Referral (AIR): A qualitative formative evaluation for implementation.Al-Anon 强化转介(AIR):实施的定性形成性评估。
J Subst Abuse Treat. 2022 Jan;132:108520. doi: 10.1016/j.jsat.2021.108520. Epub 2021 Jun 2.
8
Approaches for implementing digital interventions for alcohol use disorders in primary care: A qualitative, user-centered design study.在初级保健中实施酒精使用障碍数字干预措施的方法:一项以用户为中心的定性设计研究。
Implement Res Pract. 2022 Nov 4;3:26334895221135264. doi: 10.1177/26334895221135264. eCollection 2022 Jan-Dec.
9
Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators.纽约阿片类药物干预法庭中转介和参与物质使用障碍治疗:实施障碍和促进因素的定性研究。
Subst Abuse Treat Prev Policy. 2024 Jan 29;19(1):12. doi: 10.1186/s13011-024-00593-y.
10
American Indian and Alaska Native substance use treatment: Barriers and facilitators according to an implementation framework.美国印第安人和阿拉斯加原住民的物质使用治疗:根据实施框架的障碍和促进因素。
J Subst Use Addict Treat. 2023 Dec;155:209095. doi: 10.1016/j.josat.2023.209095. Epub 2023 Jun 3.

引用本文的文献

1
Informing the future of digital therapeutics: lessons learnt.为数字疗法的未来提供信息:经验教训。
Mhealth. 2025 Jul 11;11:43. doi: 10.21037/mhealth-25-24. eCollection 2025.

本文引用的文献

1
Prescription Digital Therapeutics for Substance Use Disorder in Primary Care: Mixed Methods Evaluation of a Pilot Implementation Study.初级保健中物质使用障碍的处方数字疗法:一项试点实施研究的混合方法评估。
JMIR Form Res. 2024 Sep 2;8:e59088. doi: 10.2196/59088.
2
Comparison of Treatment Receipt and Hospitalization Among Patients With Stimulant Use Disorder and/or Opioid Use Disorder in the Veterans Health Administration.在退伍军人健康管理局中,有兴奋剂使用障碍和/或阿片类药物使用障碍的患者在治疗接受和住院方面的比较。
J Addict Med. 2024;18(5):561-566. doi: 10.1097/ADM.0000000000001329. Epub 2024 Jun 3.
3
Use of Medication for Opioid Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021.
2021年美国过去一年患有阿片类药物使用障碍的成年人中用于阿片类药物使用障碍的药物使用情况。
JAMA Netw Open. 2023 Aug 1;6(8):e2327488. doi: 10.1001/jamanetworkopen.2023.27488.
4
Provision of Digital Health Technologies for Opioid Use Disorder Treatment by US Health Care Organizations.美国医疗机构提供数字健康技术治疗阿片类药物使用障碍。
JAMA Netw Open. 2023 Jul 3;6(7):e2323741. doi: 10.1001/jamanetworkopen.2023.23741.
5
Implementation and workflow strategies for integrating digital therapeutics for alcohol use disorders into primary care: a qualitative study.将数字治疗方法用于酒精使用障碍的实施和工作流程策略,纳入初级保健:一项定性研究。
Addict Sci Clin Pract. 2023 May 8;18(1):27. doi: 10.1186/s13722-023-00387-w.
6
FDA regulations and prescription digital therapeutics: Evolving with the technologies they regulate.美国食品药品监督管理局的法规与处方数字疗法:随其所监管的技术一同发展。
Front Digit Health. 2023 Apr 17;5:1086219. doi: 10.3389/fdgth.2023.1086219. eCollection 2023.
7
Study protocol for a factorial-randomized controlled trial evaluating the implementation, costs, effectiveness, and sustainment of digital therapeutics for substance use disorder in primary care (DIGITS Trial).一项评估初级保健中物质使用障碍数字治疗实施、成本、效果和可持续性的析因随机对照试验研究方案(DIGITS 试验)。
Implement Sci. 2023 Feb 1;18(1):3. doi: 10.1186/s13012-022-01258-9.
8
The Promise of Digital Health: Then, Now, and the Future.数字健康的前景:过去、现在与未来。
NAM Perspect. 2022 Jun 27;2022. doi: 10.31478/202206e. eCollection 2022.
9
What strategies are used by clinician champions to reduce low-value care?临床倡导者使用哪些策略来减少低价值医疗服务?
SAGE Open Med. 2022 Jan 21;10:20503121211069855. doi: 10.1177/20503121211069855. eCollection 2022.
10
Safety and efficacy of a digital therapeutic for substance use disorder: Secondary analysis of data from a NIDA clinical trials network study.数字治疗物质使用障碍的安全性和疗效:美国国家药物滥用研究所临床试验网络研究数据的二次分析。
Subst Abus. 2022;43(1):937-942. doi: 10.1080/08897077.2022.2060425.